<DOC>
	<DOCNO>NCT01838538</DOCNO>
	<brief_summary>To study efficacy safety intraperitoneal injection bevacizumab combine intraperitoneal hyperthermic perfusion chemotherapy treatment malignant ascites ovarian cancer . To analyze clinical significance concentration change vascular endothelial growth factor ( VEGF ) ascites treatment intraperitoneal injection bevacizumab</brief_summary>
	<brief_title>Clinical Study Treatment Malignant Ascites Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed informed consent obtain prior initiation studyspecific procedure treatment confirmation patient 's awareness willingness comply study requirement . Histologically confirm documented ovarian cancer malignant ascites . ECOG ( Eastern Cooperative Oncology Group , ECOG ) PS 02 . Life expectancy &gt; 3 month . No serious inadequate bone marrow function , liver renal function significant cardiovascular disease . Known hypersensitivity study drug excipients . Any current anticancer therapy . No evidence ascites . Key organ dysfunction . Significant cardiovascular disease ( e.g . congestive heart failure ( CHF ) , uncontrolled cardiac arrhythmia , angina , heart valve disease , myocardial infarction refractory hypertension need long time control medicine ) . Nonhealing wound , ulcer bone fracture . Uncontrolled psychiatric history .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>